Prescription & OTC Drug Info | Side Effects, Interactions & Dosages
WEBMPR provides drug monographs, drug news and e-prescribing service for healthcare professionals. We provides drug dosing, interactions, recalls and more for medical professionals.
September 2024 Recap: Drug Pipeline Updates - MPR
WEB3 days ago · October 10, 2024. The table below is a review of notable updates that occurred in September 2024 for investigational products in development (not an inclusive list). Click on the status to view ...
Generic Abraxane Now Available for Metastatic Breast Cancer
WEB2 days ago · The recommended dosage is 260mg/m 2 given intravenously over 30 minutes every 3 weeks. Dosage modifications are recommended for patients with moderate or severe hepatic impairment. “An estimated ...
Availability, Timeliness of Availability of New Cancer Drugs Vary
WEB2 days ago · Meng Li, PhD, from Tufts Medical Center in Boston, and colleagues examined the availability and timeliness of availability of new cancer drugs between 1990 and 2022. The number of new drugs ...
The MPR Drug Reference Database for Healthcare Practitioners
WEBMPR remains a leading authority in prescribing information for physicians, nurse practitioners, physician assistants, and other healthcare practitioners. Our drug database covers all therapeutic ...
Pharma & Medical Drug News | Pharmaceutical Health Articles
WEBOct 4, 2024 · Cancer Survival Rates Rose for Young Adults After Affordable Care Act. Pharmaceutical drug news, medical and health articles for medical professionals. Learn about drug recalls, pharma label ...
Rybelsus (semaglutide) Dosage & Prescription Information - MPR
WEBRYBELSUS prescription and dosage information for physicians and health care professionals. Pharmacology, adverse reactions, warnings, and RYBELSUSside effects.
Mepolizumab Significantly Reduces COPD Exacerbations - MPR
WEBSep 9, 2024 · Mepolizumab was found to significantly reduce exacerbations in adults with chronic obstructive pulmonary disease (COPD), according to results from the MATINEE trial. The randomized, double-blind ...
Retevmo Gets Traditional Approval for RET-Driven Medullary …
WEBSep 30, 2024 · The Food and Drug Administration (FDA) has granted traditional approval to Retevmo ® (selpercatinib) for adult and pediatric patients 2 years and older with advanced or metastatic medullary ...
Tezepelumab Gets Breakthrough Therapy Designation for COPD …
WEBAug 8, 2024 · The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tezepelumab-ekko for use as an add-on maintenance treatment in patients with moderate to very severe chronic ...